Literature DB >> 22198416

Treatment of lung cancer via telomerase inhibition: self-assembled nanoplexes versus polymeric nanoparticles as vectors for 2'-O-Methyl-RNA.

N Nafee1, M Schneider, K Friebel, M Dong, U F Schaefer, T E Mürdter, C-M Lehr.   

Abstract

Antisense oligonucleotide, 2'-O-Methyl-RNA (OMR), is known as potent telomerase inhibitor for the treatment of lung cancer but limited by poor intracellular uptake. Chitosan-coated polymeric nanoparticles were compared to chitosan solution as non-viral vectors for OMR. The study investigated the role of chitosan properties and concentration in improving the efficiency of the nanocarriers in terms of loading, viability, cellular uptake, and telomerase inhibition in human lung cancer cell lines. Certain concentration of chitosan on nanoparticle surface is necessary to significantly increase the cellular uptake. However, excessive chitosan negatively affected the transfection efficiency. Self-assembled nanoplexes with chitosan polymer are preferentially adsorbed to the cell membrane rather than being internalized. Thus, polymeric nanoparticles proved to be superior to cationic polymers as carrier for antisense oligonucleotides. Charge cannot be considered the principle factor behind improved transfection. Uptake studies carried out on air-interface cell cultures to mimic in vivo conditions supported the results on normal cultures showing enhanced uptake of nanoplexes over naked oligonucleotides. OMR nanoplexes reduced telomerase activity by ∼50% in A549 cells concluding the potential of the system as a safe, non-invasive, and efficient treatment for lung carcinoma. These data are prerequisites for the ongoing studies on lung perfusion model and in vivo experiments.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198416     DOI: 10.1016/j.ejpb.2011.11.019

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  5 in total

1.  Therapeutic nanosystems for oncology nanomedicine.

Authors:  A S Gonçalves; A S Macedo; E B Souto
Journal:  Clin Transl Oncol       Date:  2012-07-27       Impact factor: 3.405

Review 2.  Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases.

Authors:  Meenu Mehta; Devesh Tewari; Gaurav Gupta; Rajendra Awasthi; Harjeet Singh; Parijat Pandey; Dinesh Kumar Chellappan; Ridhima Wadhwa; Trudi Collet; Philip M Hansbro; S Rajesh Kumar; Lakshmi Thangavelu; Poonam Negi; Kamal Dua; Saurabh Satija
Journal:  Chem Biol Interact       Date:  2019-05-25       Impact factor: 5.192

3.  Enhancing cellular morphological changes and ablation of cancer cells via the interaction of drug co-loaded magnetic nanosystems in weak rotating magnetic fields.

Authors:  Tingting Wu; Qian Zhang; Huiping Hu; Fang Yang; Ke Li; Yu Zhang; Chen Shi
Journal:  RSC Adv       Date:  2020-04-16       Impact factor: 4.036

Review 4.  Signaling Pathway Inhibitors, miRNA, and Nanocarrier-Based Pharmacotherapeutics for the Treatment of Lung Cancer: A Review.

Authors:  Shadab Md; Nabil A Alhakamy; Shahid Karim; Gamal A Gabr; Mohammad Kashif Iqubal; Samar S A Murshid
Journal:  Pharmaceutics       Date:  2021-12-08       Impact factor: 6.321

Review 5.  Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus.

Authors:  Joydeb Majumder; Tamara Minko
Journal:  Adv Ther (Weinh)       Date:  2020-10-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.